The recent murder of Brian Thompson, CEO of UnitedHealthcare, has intensified scrutiny of the healthcare and insurance industries, exposing public frustration over high costs and systemic inefficiencies.
UnitedHealth Group’s CEO, Andrew Witty, addressed these issues during an earnings call, where he honoured Thompson’s legacy and highlighted UnitedHealth’s record $400 billion revenue and $14.5 billion net profit for the previous year.
Witty acknowledged the need for a simpler, less costly healthcare system, citing inflated U.S. procedure, prescription, and service costs as primary cost drivers compared to other nations.
He singled out pharmaceutical companies as the main culprits, emphasising disparities in GLP-1 drug prices, which are significantly higher in the U.S. than in Europe.
Through its pharmacy benefit manager Optum Rx, UnitedHealth plans to return 100% of drug rebates to consumers and employers by 2028, aiming for greater transparency in drug pricing accountability.
Witty defended PBMs as essential cost-control agents, countering accusations from lawmakers and drug manufacturers.
Witty also criticised hospitals, suggesting they resist reforms aimed at enabling lower-cost care sites, as such measures could jeopardise their revenue streams.
He endorsed proposals to make Medicare more cost-effective, a contentious issue within the healthcare sector.
The call highlights the broader industry debate over pricing and accountability, underscoring UnitedHealth’s commitment to driving change amid heightened public and regulatory scrutiny.